Nucala Market Report 2026

Nucala Market Overview

• The Nucala market growth in the historic period has been driven by rising prevalence of severe eosinophilic asthma, increased recognition of eosinophilic disorders • Market expansion is supported by increasing expansion into additional eosinophilic indications, rising demand for personalized respiratory biologics • Growth Driver: Growing Asthma Prevalence Fuels Market Growth • Market Trend: Development Of Ready-To-Use Injectable Formulations In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Nucala Market?

Nucala (mepolizumab) is a monoclonal antibody biologic therapy that targets and inhibits interleukin-5 (IL-5), a key cytokine involved in the growth, activation, and survival of eosinophils. By reducing eosinophilic inflammation, it helps manage symptoms and reduce the frequency of exacerbations in patients with severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and other eosinophil-driven conditions. The main types of indications for nucala are severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), chronic obstructive pulmonary disease (COPD), and other eosinophilic disorders. Severe asthma is a form of asthma that is difficult to control, requires higher medication doses, and is characterized by persistent symptoms like wheezing and breathlessness despite standard treatments. It is distributed through various channels such as direct sales, retail pharmacies, and online pharmacies and is used by various end users including hospitals, clinics, and home care settings.

What Is The Nucala Market Growth Forecast?

The growth in the forecast period can be attributed to increasing expansion into additional eosinophilic indications, rising demand for personalized respiratory biologics, advancements in monoclonal antibody engineering, broader global reimbursement coverage, increased home-based administration adoption. Major trends in the forecast period include increasing adoption of targeted biologic asthma therapies, growing use of IL-5 inhibitors in chronic conditions, expansion of precision medicine approaches in respiratory care, rising focus on long-term disease control, enhanced patient stratification practices.

Global Nucala Market Segmentation

1) By Indication: Severe Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Chronic Obstructive Pulmonary Disease (COPD), Other Eosinophilic Disorders 2) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Pharmacies 3) By End User: Hospitals, Clinics, Home Care Settings

What Are The Drivers Of The Nucala Market?

The increasing prevalence of asthma is expected to propel the growth of the nucala market going forward. Asthma is a chronic respiratory condition causing airway inflammation and narrowing, leading to symptoms such as wheezing, coughing, chest tightness, and shortness of breath, often triggered by allergens or physical activity. The increase in the prevalence of asthma is attributed to factors such as environmental pollution, allergens, changes in lifestyle, urbanization, and genetic predisposition. Nucala works to reduce asthma by targeting and inhibiting interleukin-5 (IL-5), a key protein involved in the growth and activation of eosinophils, which are white blood cells that contribute to airway inflammation in asthma, thereby reducing symptoms and the frequency of asthma exacerbations. For instance, in February 2023, according to the NHS England, a UK-based government department, In the UK, 5.4 million people receive asthma treatment, with around 160,000 new diagnoses annually, and work-related asthma accounts for 9-15% of adult-onset cases. Therefore, the increasing prevalence of asthma is driving growth in the nucala industry. The increasing prevalence of eosinophilic disorders is expected to propel the growth of the nucala market going forward. Eosinophilic disorders refer to a group of medical conditions characterized by the overproduction and accumulation of eosinophils, a type of white blood cell, in various tissues, leading to inflammation and potential damage. The increasing prevalence of eosinophilic disorders is attributed to factors such as rising environmental allergens, changes in dietary habits, genetic predispositions, and heightened awareness leading to improved diagnostic rates. Nucala (mepolizumab) treats eosinophilic disorders by targeting and inhibiting interleukin-5 (IL-5), a cytokine responsible for the growth and survival of eosinophils, thereby reducing eosinophil levels and alleviating associated symptoms. For instance, in December 2023, according to the PubMed, a US-based government-operated, non-profit online database, reported that the global pooled incidence and prevalence of EoE were 5.31 cases per 100,000 inhabitant-years. Therefore, the increasing prevalence of eosinophilic disorders is driving growth in the nucala industry.

Key Players In The Global Nucala Market

Major companies operating in the nucala market are GlaxoSmithKline plc

Global Nucala Market Trends and Insights

Major companies operating in the Nucala market are focusing on developing innovative solutions, such as ready-to-use injectable formulations, to meet the rising demand for patient convenience and improved treatment adherence. A ready-to-use injectable form is a pre-prepared pharmaceutical product that requires no further dilution or mixing before administration. For instance, in May 2025, GlaxoSmithKline Plc, a UK-based pharmaceutical company, received approval from the US FDA for Nucala (mepolizumab) for the treatment of adults with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype. This indication expansion allows targeted therapy for COPD patients with high unmet need, supported by positive results from the MATINEE and METREX Phase III trials.

Regional Insights

North America was the largest region in the nucala market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Nucala Market?

The nucala market consists of sales of nucala 100mg injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nucala Market Report 2026?

The nucala market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nucala industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.